Showing 8 of 68 recruiting trials for “b-cell-non-hodgkin-lymphoma”
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
👨⚕️ Ryan Lynch, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Oct 2020View details ↗
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
👨⚕️ Sarit Assouline, The Jewish General Hospital, Montreal QC, Canada📍 4 sites📅 Started Sep 2020View details ↗
A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL
A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
👨⚕️ Christopher J Melani, M.D., National Cancer Institute (NCI)📍 1 site📅 Started Feb 2018View details ↗
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
← PreviousPage 4 of 4
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →